$6.09
4.64% today
Nasdaq, Aug 12, 04:17 pm CET

NeoGenomics, Inc. Stock price

$5.82
-1.44 19.83% 1M
-7.66 56.82% 6M
-10.66 64.68% YTD
-10.11 63.47% 1Y
-6.47 52.64% 3Y
-33.41 85.16% 5Y
-0.17 2.84% 10Y
+5.31 1,041.18% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.02 0.34%

Key metrics

Basic
Market capitalization
$751.8m
Enterprise Value
$929.2m
Net debt
$177.4m
Cash
$163.7m
Shares outstanding
128.7m
Valuation (TTM | estimate)
P/E
negative | 36.3
P/S
1.1 | 1.0
EV/Sales
1.4 | 1.2
EV/FCF
negative
P/B
0.9
Financial Health
Equity Ratio
55.1%
Return on Equity
-8.7%
ROCE
-7.1%
ROIC
-7.6%
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$689.2m | $751.9m
EBITDA
$-78.6m | $44.8m
EBIT
$-92.3m | $-115.8m
Net Income
$-104.0m | $20.6m
Free Cash Flow
$-19.2m
Growth (TTM | estimate)
Revenue
9.7% | 13.8%
EBITDA
-6.9% | 190.2%
EBIT
-4.8% | -35.5%
Net Income
-32.5% | 126.2%
Free Cash Flow
35.5%
Margin (TTM | estimate)
Gross
43.9%
EBITDA
-11.4% | 6.0%
EBIT
-13.4%
Net
-15.1% | 2.7%
Free Cash Flow
-2.8%
More
EPS
$-0.8
FCF per Share
$-0.1
Short interest
4.6%
Employees
2k
Rev per Employee
$300.0k
Show more

Is NeoGenomics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

NeoGenomics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a NeoGenomics, Inc. forecast:

9x Buy
47%
9x Hold
47%
1x Sell
5%

Analyst Opinions

19 Analysts have issued a NeoGenomics, Inc. forecast:

Buy
47%
Hold
47%
Sell
5%

Financial data from NeoGenomics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
689 689
10% 10%
100%
- Direct Costs 387 387
7% 7%
56%
303 303
13% 13%
44%
- Selling and Administrative Expenses 346 346
11% 11%
50%
- Research and Development Expense 35 35
25% 25%
5%
-79 -79
7% 7%
-11%
- Depreciation and Amortization 14 14
6% 6%
2%
EBIT (Operating Income) EBIT -92 -92
5% 5%
-13%
Net Profit -104 -104
32% 32%
-15%

In millions USD.

Don't miss a Thing! We will send you all news about NeoGenomics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NeoGenomics, Inc. Stock News

Neutral
Business Wire
13 days ago
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company's PanTracer portfolio.
Neutral
Seeking Alpha
14 days ago
NeoGenomics, Inc. (NASDAQ:NEO ) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Anthony P. Zook - CEO & Director Jeffrey S.
Neutral
Business Wire
14 days ago
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its second-quarter results for the period ended June 30, 2025.
More NeoGenomics, Inc. News

Company Profile

NeoGenomics, Inc. is a clinical laboratory company, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Head office United States
CEO Anthony Zook
Employees 2,200
Founded 1998
Website neogenomics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today